CEP-33779 is primarily used in research settings as a selective inhibitor of JAK2 (Janus kinase 2), an enzyme involved in various cellular signaling pathways. Its application is significant in studying diseases where JAK2 plays a critical role, such as myeloproliferative disorders, certain types of leukemia, and autoimmune conditions. Researchers utilize CEP-33779 to investigate the mechanisms of JAK2 signaling and to evaluate its potential as a therapeutic target. Additionally, it aids in the development of novel treatments by providing insights into the inhibition of JAK2-dependent pathways. Its specificity makes it a valuable tool for understanding the role of JAK2 in inflammation, hematopoiesis, and immune responses.